Cargando…

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE(2)-receptor E-type 4 (EP4), in patients with advanced cancers

BACKGROUND: E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safety, tolerability, pharmacokinetics, pharmacodynami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, David S, Parikh, Aparna, Shapiro, Geoffrey I, Varga, Andrea, Naing, Aung, Meric-Bernstam, Funda, Ataman, Özlem, Reyderman, Larisa, Binder, Terri A, Ren, Min, Liu, Mingjie, Dayal, Satish, Siu, Amy Y, Sachdev, Pallavi, Xu, Lucy, Bhagawati-Prasad, Vijay, Tchakov, Ilian, Ooi, Chean Eng, Bao, Xingfeng, Marabelle, Aurelien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304851/ https://www.ncbi.nlm.nih.gov/pubmed/32554609 http://dx.doi.org/10.1136/jitc-2019-000222

Ejemplares similares

EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity
por: Albu, Diana I., et al.
Publicado: (2017)

High-Temperature Compression Behaviors and Constitutive Models of a 7046-Aluminum Alloy
por: He, Daoguang, et al.
Publicado: (2023)

Changing prostaglandin E2 (PGE(2)) signaling during lesional progression and exacerbation of endometriosis by inhibition of PGE(2) receptor EP2 and EP4
por: Huang, Qingqing, et al.
Publicado: (2021)

The role of prostaglandin E(2 )(PGE (2)) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia
por: Hernandez, Yasmin, et al.
Publicado: (2010)

A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE(2)-mediated immunosuppression and inhibits breast cancer metastasis
por: Ma, Xinrong, et al.
Publicado: (2013)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation
por: Cuglievan, Branko, et al.
Publicado: (2018)

Strategies for improving the management of immune-related adverse events
por: Naing, Aung, et al.
Publicado: (2020)

Mammalian oocytes are targets for prostaglandin E2 (PGE2) action
por: Duffy, Diane M, et al.
Publicado: (2010)

Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF Progression
por: Moshkovitz, Noa, et al.
Publicado: (2023)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma
por: Nze, Chijioke, et al.
Publicado: (2023)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Cytokine gene regulation by PGE(2), LTB(4) and PAF
por: Rola-Pleszczynski, M., et al.
Publicado: (1992)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

(E)-4-[(4-Amino-5-bromopyridin-3-yl)iminomethyl]phenol
por: Cai, Mingjian, et al.
Publicado: (2008)

Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer
por: Ke, Jieqi, et al.
Publicado: (2016)

Active Smoking Increases Microsomal PGE(2)-Synthase-1/PGE-Receptor-4 Axis in Human Abdominal Aortic Aneurysms
por: Dilmé, Jaime-Félix, et al.
Publicado: (2014)

The Wae to repair: prostaglandin E2 (PGE(2)) triggers intestinal wound repair
por: Jackstadt, Rene, et al.
Publicado: (2017)

4E-BP restrains eIF4E phosphorylation
por: Müller, David, et al.
Publicado: (2013)

Retraction notice for: “lncRNA CCAT1 promotes cell proliferation, migration, and invasion by down-regulation of miR-143 in FTC-133 thyroid carcinoma cell line” [Braz J Med Biol Res (2018) 51(6): e7046]
Publicado: (2021)

Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE(2)-dependent IgE inhibition in pancreatic cancer
por: De Monte, Lucia, et al.
Publicado: (2023)

Synergistic activation of eIF4A by eIF4B and eIF4G
por: Nielsen, Klaus H., et al.
Publicado: (2011)

The effect of cocaine on gastric mucosal PGE(2), LTC(4) and ulcerations
por: Angus, L. D. G., et al.
Publicado: (1993)

Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway
por: Liang, Mingjie, et al.
Publicado: (2023)

Prostaglandin E(2) (PGE(2)) Exerts Biphasic Effects on Human Tendon Stem Cells
por: Zhang, Jianying, et al.
Publicado: (2014)

An Update of Microsomal Prostaglandin E Synthase-1 and PGE(2) Receptors in Cardiovascular Health and Diseases
por: Yang, Guangrui, et al.
Publicado: (2016)

Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma
por: Kawamoto, Hironori, et al.
Publicado: (2019)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

Selectivity for eIF4E
por: LeBrasseur, Nicole
Publicado: (2005)

Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer
por: Kochel, Tyler J, et al.
Publicado: (2016)

Human eukaryotic initiation factor 4E (eIF4E) and the nucleotide-bound state of eIF4A regulate eIF4F binding to RNA
por: Izidoro, Mario Servulo, et al.
Publicado: (2022)

Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites
por: Walji, Muhammad, et al.
Publicado: (2004)

Evolutionary changes in the Leishmania eIF4F complex involve variations in the eIF4E–eIF4G interactions
por: Yoffe, Yael, et al.
Publicado: (2009)

Proneoplastic effects of PGE(2 )mediated by EP4 receptor in colorectal cancer
por: Doherty, Glen A, et al.
Publicado: (2009)

The role of PGE(2) EP(4) receptors in the regulation of endothelial barrier function
por: Kampitsch, Nora, et al.
Publicado: (2012)

PGE2 activates EP4 in subchondral bone osteoclasts to regulate osteoarthritis
por: Jiang, Wenhao, et al.
Publicado: (2022)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity
por: Coleman, L J, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_6ifep8o5f881sst296f36prmal